Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Morphosys Ag ADR (NQ: MOR )

7.340 -0.150 (-2.00%)
Streaming Delayed Price Updated: 9:35 AM EDT, Jun 9, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Morphosys Ag ADR

< Previous 1 2 3 Next >
MorphoSys AG Reports First Quarter 2023 Financial Results
From MorphoSys AG
Via Business Wire
Invitation to MorphoSys’ First Quarter 2023 Financial Results Conference Call on May 4, 2023
Via ACCESSWIRE
MorphoSys and Incyte Announce Five-Year Results of L-MIND Study Showed Prolonged, Durable Responses in Relapsed or Refractory DLBCL Patients Treated with Monjuvi® (tafasitamab-cxix)
From Incyte and MorphoSys U.S. Inc.
Via Business Wire
MorphoSys AG Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update
From MorphoSys AG
Via Business Wire
Invitation to MorphoSys' Full Year Results 2022 Conference Call on March 16, 2023
Via ACCESSWIRE
MorphoSys AG: Financial Calendar 2023
Via ACCESSWIRE
MorphoSys’ Licensing Partner Roche Provides Update on Phase 3 GRADUATE Program for Gantenerumab in Early Alzheimer’s Disease
Via ACCESSWIRE
MorphoSys Stops Work and Operations on Pre-Clinical Research Programs
Via ACCESSWIRE
Ad hoc: MorphoSys Stops Work and Operations on Pre-Clinical Research Programs and Reduces Workforce at its Germany Headquarters
Via ACCESSWIRE
MorphoSys AG: MorphoSys Expects Topline Data from Phase 3 Study of Pelabresib in Myelofibrosis in Early 2024
Via ACCESSWIRE
MorphoSys Reports Preliminary 2022 Monjuvi U.S. Net Product Sales, Provides 2023 Financial Guidance and Reduces Financial Liability
Via ACCESSWIRE
Invitation to MorphoSys’ Third Quarter and First Nine Months 2022 Results Conference Call on November 17, 2022
Via ACCESSWIRE
MorphoSys Reports Preliminary Q3 2022 Monjuvi U.S. Sales and Updates Financial Guidance for 2022
Via ACCESSWIRE
MorphoSys AG: Invitation to MorphoSys' Second Quarter and First Half Year 2022 Results Conference Call on August 4 , 2022
Via ACCESSWIRE
MorphoSys AG Reports Preliminary Q2 2022 Monjuvi U.S. Sales and Updates Financial Guidance for 2022
Via ACCESSWIRE
MorphoSys AG Reports First Nine Months and Third Quarter 2022 Financial Results
From MorphoSys AG
Via Business Wire
MorphoSys to Share New Data on Pelabresib and Monjuvi(R) (tafasitamab-cxix) in 14 Presentations at the American Society of Hematology Annual Meeting
Via ACCESSWIRE
MorphoSys Presents Preliminary Results from Phase 1/2 Study of Tulmimetostat (CPI-0209) Supporting Its Potential Application in a Broad Array of Advanced Tumors
Via ACCESSWIRE
GSK, MorphoSys' Licensing Partner, Provides Update on ContRAst Phase III Program for Otilimab in Moderate to Severe Rheumatoid Arthritis
Via ACCESSWIRE
MorphoSys AG Reports Second Quarter and First Half 2022 Financial Results
From MorphoSys AG
Via Business Wire
Devon Energy Produces A Record Quarter, Dividend Raised By 22%
Devon Energy produced another record quarter of profits, as higher volumes and prices provided significant tailwinds to results. 
Via MarketBeat
MorphoSys AG: Invitation to MorphoSys' Second Quarter and First Half Year 2022 Results Conference Call on August 4 , 2022
Conference Call Alert 
From MorphoSys AG
Via AccessWire
MorphoSys Reports Preliminary Q2 2022 Monjuvi U.S. Sales and Updates Financial Guidance for 2022
PLANEGG/MUNICH, GERMANY / ACCESSWIRE / July 26, 2022 / MorphoSys AG (FSE:MOR)(NASDAQ:MOR) today reported preliminary U.S. net product sales of Monjuvi® (tafasitamab-cxix) for the second quarter 2022... 
From MorphoSys AG
Via AccessWire
MorphoSys Reports Preliminary Q2 2022 Monjuvi U.S. Sales and Updates Financial Guidance for 2022
Via ACCESSWIRE
MorphoSys AG Reports Preliminary Q2 2022 Monjuvi U.S. Sales and Updates Financial Guidance for 2022
Publication of an inside information according to Article 17 para. 1 of the Regulation (EU) No. 596/2014 
From MorphoSys AG
Via AccessWire
MorphoSys and HIBio Enter Into Equity Participation and License Agreements for Felzartamab and MOR210
From MorphoSys AG
Via Business Wire
MorphoSys Presents Multiple Analyses of the MANIFEST Phase 2 Trial Investigating the Potential of Pelabresib in the Treatment of Myelofibrosis at EHA 2022
From MorphoSys
Via Business Wire
MorphoSys AG Reports Outcome of Annual General Meeting 2022
PLANEGG/MUNICH, GERMANY / ACCESSWIRE / May 18, 2022 / MorphoSys AG (FSE:MOR); (NASDAQ:MOR) announced today that its shareholders approved all resolutions proposed by the Company´s Management and... 
From MorphoSys AG
Via AccessWire
MorphoSys to Present New Data on Pelabresib and Monjuvi® (tafasitamab-cxix) at the 2022 European Hematology Association (EHA) and American Society of Clinical Oncology (ASCO) Annual Meetings
From MorphoSys
Via Business Wire
MorphoSys AG Reports First Quarter 2022 Financial Results
From MorphoSys AG
Via Business Wire
< Previous 1 2 3 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.